CRP and rheumatoid arthritis: A post hoc analysis of four Phase 3 trials of upadacitinib demonstrated improvements in efficacy (ACR20 response, LDA and clinical remission), radiographic progression, patient-reported functioning, and pain vs placebo in those with moderate RA activity (DAS28-CRP >3.2 to ≤5.1) and an inadequate response to bDMARDs and/or csDMARDs, although the treatment period was shorter (12/14/26 weeks) than for this analysis (52 weeks) [37].